Preview

Кардиология

Расширенный поиск

Когнитивная дисфункция на фоне фибрилляции предсердий: клинико-патогенетические ассоциации, диагностика и профилактика, аспекты применения антикоагулянтной терапии

https://doi.org/10.18087/cardio.2019.10.n612

Полный текст:

Аннотация

Фибрилляция предсердий и когнитивная дисфункция - распространенные состояния, имеющие схожие факторы риска. В последнее время получены достоверные эпидемиологические данные в пользу независимого влияния мерцательной аритмии на возможность развития когнитивных нарушений. В обзоре освещены вопросы распространенности, патогенеза и диагностики различных видов когнитивной дисфункции на фоне фибрилляции предсердий, а также способы их предупреждения и тактика применения антикоагулянтной терапии при наличии когнитивных расстройств.

Об авторах

Ж. Д. Кобалава
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов» (РУДН)
Россия

Жанна Давидовна Кобалава - доктор медицинских наук, профессор, заведующая кафедрой внутренних болезней с курсами кардиологии и функциональной диагностики имени академика В.С. Моисеева медицинского института.

Москва



П. В. Лазарев
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов» (РУДН)
Россия

Павел Валерьевич Лазарев - кандидат медицинских наук, ассистент кафедры внутренних болезней с курсами кардиологии и функциональной диагностики имени академика В.С. Моисеева медицинского института.

Москва

ResearcherID: G-3242-2015



Д. Н. Федорова
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов» (РУДН)
Россия

Дарья Николаевна Федорова - кафедра внутренних болезней с курсами кардиологии и функциональной диагностики имени академика В.С. Моисеева медицинского института.

Москва



Список литературы

1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S et al. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137(l2):e67-492. DOI: 10.1161/CIR.0000000000000558

2. Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. European Heart Journal. 2013;34(35):2746-51. DOI: 10.1093/eurheartj/eht280

3. Wu Y-T, Fratiglioni L, Matthews FE, Lobo A, Breteler MMB, Skoog I et al. Dementia in western Europe: epidemiological evidence and implications for policy making. The Lancet Neurology. 2016;15(1):116-24. DOI: 10.1016/S1474-4422(15)00092-7

4. Diener H-C, Hart RG, Koudstaal PJ, Lane DA, Lip GYH. Atrial Fibrillation and Cognitive Function. Journal of the American College of Cardiology. 2019;73(5):612-9. DOI: 10.1016/j.jacc.2018.10.077

5. Silva RMFLD, Miranda CM, Liu T, Tse G, Roever L. Atrial Fibrillation and Risk of Dementia: Epidemiology, Mechanisms, and Effect of Anticoagulation. Frontiers in Neuroscience. 2019;13:18. DOI: 10.3389/fnins.2019.00018

6. Остроумова О.Д., Черняева М.С., Головина О.В. Фибрилляция предсердий как фактор риска развития когнитивных нарушений и деменции. Возможности антикоагулянтной терапии в их профилактике. Кардиология. 2018;58(9):76-88. DOI: 10.18087/cardio.2018.9.10173

7. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clinical Epidemiology. 2014;6:213-20. DOI: 10.2147/CLEP.S47385

8. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer's & Dementia. 2013;9(1):63-75.e2. DOI: 10.1016/j.jalz.2012.11.007

9. Erkinjuntti T, 0stbye T, Steenhuis R, Hachinski V. The Effect of Different Diagnostic Criteria on the Prevalence of Dementia. New England Journal of Medicine. 1997;337(23):1667-74. DOI: 10.1056/NEJM199712043372306

10. de Bruijn RF, Bos MJ, Portegies ML, Hofman A, Franco OH, Koudstaal PJ et al. The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. BMC Medicine. 2015;13(1):132. DOI: 10.1186/s12916-015-0377-5

11. Hahn L, Kessler J. A new scoring system for increasing the sensitivity of the MMSE. Zeitschrift fur Gerontologie und Geriatrie. 2019; [Epub ahead of print]. DOI: 10.1007/s00391-019-01516-4

12. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. Journal of the American Geriatrics Society. 2005;53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x

13. Nishtala A, Piers RJ, Himali JJ, Beiser AS, Davis-Plourde KL, Saczynski JS et al. Atrial fibrillation and cognitive decline in the Framingham Heart Study. Heart Rhythm. 2018;15(2):166-72. DOI: 10.1016/j.hrthm.2017.09.036

14. Dagres N, Chao T-F, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ et al. European Heart Rhythm Association (EH^A)/ Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? EP Europace. 2018;20(9):1399-421. DOI: 10.1093/europace/euy046

15. Madhavan M, Graff-Radford J, Piccini JP, Gersh BJ. Cognitive dysfunction in atrial fibrillation. Nature Reviews Cardiology. 2018;15(12):744-56. DOI: 10.1038/s41569-018-0075-z

16. Ratcliffe PJ, Wilcock GK. Cerebrovascular disease in dementia: the importance of atrial fibrillation. Postgraduate Medical Journal. 1985;61(713):201-4. DOI: 10.1136/pgmj.61.713.201

17. Thacker EL, McKnight B, Psaty BM, Longstreth WT, Sitlani CM, Dublin S et al. Atrial fibrillation and cognitive decline: A longitudinal cohort study. Neurology. 2013;81(2):119-25. DOI: 10.1212/WNL.0b013e31829a33d1

18. Marzona I, O'Donnell M, Teo K, Gao P, Anderson C, Bosch J et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. Canadian Medical AssociationJournal. 2012;184(6):E329-36. DOI: 10.1503/cmaj.111173

19. Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm. 2010;7(4):433-7. DOI: 10.1016/j.hrthm.2009.12.004

20. Santangeli P, Di Biase L, Bai R, Mohanty S, Pump A, Cereceda Brantes M et al. Atrial fibrillation and the risk of incident dementia: A meta-analysis. Heart Rhythm. 2012;9(11):1761-1768.e2. DOI: 10.1016/j.hrthm.2012.07.026

21. Kalantarian S, Stern TA, Mansour M, Ruskin JN. Cognitive Impairment Associated With Atrial Fibrillation: A Meta-analysis. Annals of Internal Medicine. 2013;158(5_Part_1):338. DOI: 10.7326/0003-4819-158-5-201303050-00007

22. Liao J-N, Chao T-F, Liu C-J, Wang K-L, Chen S-J, Tuan T-C et al. Risk and prediction of dementia in patients with atrial fibrillation -A nationwide population-based cohort study. International Journal ofCardiology. 2015;199:25-30. DOI: 10.1016/j.ijcard.2015.06.170

23. Деменко Т.Н., Чумакова Г.А., Веселовская Н.Г. Особенности когнитивных функций, качества жизни и психологического состояния пациентов с разными формами фибрилляции предсердий. Сердце: Журнал для практических врачей. 2017;16(2):123-34. DOI: 10.18087/rhj.2017.2.2336

24. Chen LY, Norby FL, Gottesman RF, Mosley TH, Soliman EZ, Agarwal SK et al. Association of Atrial Fibrillation With Cognitive Decline and Dementia Over 20 Years: The ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study). Journal of the American Heart Association. 2018;7(6):e007301. DOI: 10.1161/JAHA.117.007301

25. Singh-Manoux A, Fayosse A, Sabia S, Canonico M, Bobak M, Elbaz A et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. European Heart Journal. 2017;38(34):2612-8. DOI: 10.1093/eurheartj/ehx208

26. Alonso A, Knopman DS, Gottesman RF, Soliman EZ, Shah AJ, O'Neal WT et al. Correlates of Dementia and Mild Cognitive Impairment in Patients With Atrial Fibrillation: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). Journal of the American Heart Association. 2017;6(7):e006014. DOI: 10.1161/JAHA.117.006014

27. Bunch TJ, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD et al. Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications. Journal of the American Heart Association. 2016;5(7):e003932. DOI: 10.1161/JAHA.116.003932

28. Ding M, Fratiglioni L, Johnell K, Santoni G, FastbomJ, Ljungman P et al. Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study. Neurology. 2018;91(19):e1732-40. DOI: 10.1212/WNL.0000000000006456

29. Poggesi A, Inzitari D, Pantoni L. Atrial Fibrillation and Cognition: Epidemiological Data and Possible Mechanisms. Stroke. 2015;46(11):3316-21. DOI: 10.1161/STROKEAHA.115.008225

30. Kalantarian S, Ruskin JN. Atrial Fibrillation and Cognitive Decline. Cardiology Clinics. 2016;34(2):279-85. DOI: 10.1016/j.ccl.2015.12.011

31. Kwok CS, Loke YK, Hale R, Potter JF, Myint PK. Atrial fibrillation and incidence ofdementia: Asystematic review and meta-analysis. Neurology. 2011;76(10):914-22. DOI: 10.1212/WNL.0b013e31820f2e38

32. Silva DS, Coan AC, Avelar WM. Neuropsychological and neuroimaging evidences of cerebral dysfunction in stroke-free patients with atrial fibrillation: A review. Journal of the Neurological Sciences. 2019;399:172-81. DOI: 10.1016/j.jns.2019.02.027

33. Miyasaka Y, Barnes ME, Petersen RC, Cha SS, Bailey KR, Gersh BJ et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort. European Heart Journal. 2007;28(16):1962-7. DOI: 10.1093/eurheartj/ehm012

34. Gaita F, Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E et al. Prevalence of Silent Cerebral Ischemia in Paroxysmal and Persistent Atrial Fibrillation and Correlation With Cognitive Function. Journal of the American College of Cardiology. 2013;62(21):1990-7. DOI: 10.1016/j.jacc.2013.05.074

35. Kalantarian S, Ay H, Gollub RL, Lee H, Retzepi K, Mansour M et al. Association Between Atrial Fibrillation and Silent Cerebral Infarctions: A Systematic Review and Meta-analysis. Annals of Internal Medicine. 2014;161(9):650-8. DOI: 10.7326/M14-0538

36. Conen D, Rodondi N, Muller A, BeerJH, AmmannP, Moschovitis G et al. Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2019;73(9):989-99. DOI: 10.1016/j.jacc.2018.12.039

37. van Veluw SJ, Shih AY, Smith EE, Chen C, SchneiderJA, WardlawJM et al. Detection, risk factors, and functional consequences of cerebral microinfarcts. The Lancet Neurology. 2017;16(9):730-40. DOI: 10.1016/S1474-4422(17)30196-5

38. de Bruijn RFAG, Portegies MLP, Leening MJG, Bos MJ, Hofman A, van der Lugt A et al. Subclinical cardiac dysfunction increases the risk of stroke and dementia: The Rotterdam Study. Neurology. 2015;84(8):833-40. DOI: 10.1212/WNL.0000000000001289

39. Knecht S, Oelschlager C, Duning T, Lohmann H, AlbersJ, Stehling C et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. European Heart Journal. 2008;29(17):2125-32. DOI: 10.1093/eurheartj/ehn341

40. Alosco ML, Spitznagel MB, Sweet LH, Josephson R, Hughes J, Gunstad J. Atrial Fibrillation Exacerbates Cognitive Dysfunction and Cerebral Perfusion in Heart Failure. Pacing and Clinical Electrophysiology. 2015;38(2):178-86. DOI: 10.1111/pace.12543

41. Stefansdottir H, Arnar DO, Aspelund T, Sigurdsson S, Jonsdottir MK, Hjaltason H et al. Atrial Fibrillation is Associated With Reduced Brain Volume and Cognitive Function Independent of Cerebral Infarcts. Stroke. 2013;44(4):1020-5. DOI: 10.1161/STROKEAHA.12.679381

42. Gardarsdottir M, Sigurdsson S, Aspelund T, Rokita H, Launer LJ, Gudnason V et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. EP Europace. 2018;20(8):1252-8. DOI: 10.1093/europace/eux220

43. Piers RJ, Nishtala A, Preis SR, DeCarli C, Wolf PA, Benjamin EJ et al. Association between atrial fibrillation and volumetric magnetic resonance imaging brain measures: Framingham Offspring Study. Heart Rhythm. 2016;13(10):2020-4. DOI: 10.1016/j.hrthm.2016.07.004

44. de la TorreJC. Alzheimer Disease as a Vascular Disorder: Nosological Evidence. Stroke. 2002;33(4):1152-62. DOI: 10.1161/01.STR.0000014421.15948.67

45. Dietzel J, Haeusler KG, Endres M. Does atrial fibrillation cause cognitive decline and dementia? EP Europace. 2018;20(3):408-19. DOI: 10.1093/europace/eux031

46. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. Journal of the American College of Cardiology. 2012;60(22):2263-70. DOI: 10.1016/j.jacc.2012.04.063

47. Kornej J, Reinhardt C, Kosiuk J, Arya A, Hindricks G, Adams V et al. Response of High-Sensitive C-Reactive Protein to Catheter Ablation of Atrial Fibrillation and Its Relation with Rhythm Outcome. PLoS ONE. 2012;7(8):e44165. DOI: 10.1371/journal.pone.0044165

48. Marcus GM, Smith LM, Ordovas K, Scheinman MM, Kim AM, Badhwar N et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2010;7(2):149-54. DOI: 10.1016/j.hrthm.2009.10.004

49. Rotter M, Jais P, Vergnes M-C, Nurden P, Takahashi Y, Sanders P et al. Decline in C-Reactive Protein After Successful Ablation of Long-Lasting Persistent Atrial Fibrillation. Journal of the American College of Cardiology. 2006;47(6):1231-3. DOI: 10.1016/j.jacc.2005.12.038

50. Pinto A, Tuttolomondo A, Casuccio A, Di Raimondo D, Di Sciacca R, Arnao V et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clinical Science. 2009;116(10):781-9. DOI: 10.1042/CS20080372

51. Yang J, Hossein Noyan-Ashraf M, Meissner A, Voigtlaender-Bolz J, Kroetsch JT, Foltz W et al. Proximal Cerebral Arteries Develop Myogenic Responsiveness in Heart Failure via Tumor Necrosis Factor-a-Dependent Activation of Sphingosine-1-Phosphate Signaling. Circulation. 2012;126(2):196-206. DOI: 10.1161/CIRCULATIONAHA.111.039644

52. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA et al. EH^A/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18(10):1455-90. DOI: 10.1093/europace/euw161

53. Silva DS, Avelar WM, de Campos BM, Lino APBL, Balthazar MLF, Figueiredo MJO et al. Default Mode Network Disruption in Stroke-Free Patients with Atrial Fibrillation. Cerebrovascular Diseases. 2018;45(1-2):78-84. DOI: 10.1159/000486689

54. Banerjee G, Chan E, Ambler G, Wilson D, Cipolotti L, Shakeshaft C et al. Effect of small-vessel disease on cognitive trajectory after atrial fibrillation-related ischaemic stroke or TIA. Journal of Neurology. 2019;266(5):1250-9. DOI: 10.1007/s00415-019-09256-6

55. Rollo J, Knight S, May HT, Anderson JL, Muhlestein JB, Bunch TJ et al. Incidence of Dementia in Relation to Genetic Variants at PITX2, ZFHX3, and ApoE e4 in Atrial Fibrillation Patients. Pacing and Clinical Electrophysiology. 2015;38(2):171-7. DOI: 10.1111/pace.12537

56. Proietti M, Recchia A, Riva E, Lucca U, Tettamanti M, Mannucci PM et al. Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. European Journal of Internal Medicine. 2017;46:6-10. DOI: 10.1016/j.ejim.2017.08.010

57. Graves KG, May HT, Jacobs V, Bair TL, Stevens SM, Woller SC et al. Atrial fibrillation incrementally increases dementia risk across all CHADS 2 and CHA 2 DS 2 VASc strata in patients receiving long-term warfarin. American Heart Journal. 2017;188:93-8. DOI: 10.1016/j.ahj.2017.02.026

58. Ball J, Carrington MJ, Stewart S, on behalf of the SAFETY investigators. Mild cognitive impairment in high-risk patients with chronic atrial fibrillation: a forgotten component of clinical management? Heart. 2013;99(8):542-7. DOI: 10.1136/heartjnl-2012-303182

59. Heiss W-D, Rosenberg GA, Thiel A, Berlot R, de ReuckJ. Neuroimaging in vascular cognitive impairment: a state-of-the-art review. BMC Medicine. 2016;14(1):174. DOI: 10.1186/s12916-016-0725-0

60. Salas M. Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study. Clinical Pharmacology & Therapeutics. 2001;70(6):561-6. DOI: 10.1067/mcp.2001.119812

61. El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication Adherence in Older Patients With Dementia: A Systematic Literature Review. Journal of Pharmacy Practice. 2018;31(3):322-34. DOI: 10.1177/0897190017710524

62. Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB et al. Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes. 2010;3(3):277-83. DOI: 10.1161/CIRCOUTCOMES.109.884171

63. Orkaby AR, Ozonoff A, Reisman JI, Miller DR, Zhao S, Rose AJ. Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. Journal of the American Geriatrics Society. 2017;65(2):249-56. DOI: 10.1111/jgs.14573

64. Subic A, Cermakova P, Religa D, Han S, von Euler M, Kareholt I et al. Treatment ofAtrial Fibrillation in Patients with Dementia: A Cohort Study from the Swedish Dementia Registry. Journal of Alzheimer's Disease. 2018;61(3):1119-28. DOI: 10.3233/JAD-170575

65. Rivera-Caravaca JM, Roldan V, Esteve-Pastor MA, Valdes M, Vicente V, Marin F et al. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. Clinical Therapeutics. 2018;40(1):114-22. DOI: 10.1016/j.clinthera.2017.11.014

66. Raparelli V, Proietti M, Cangemi R, Lip GYH, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation: Focus on non-vitamin K antagonist oral anticoagulants. Thrombosis and Haemostasis. 2017;117(02):209-18. DOI: 10.1160/TH16-10-0757

67. Allali G, Launay CP, Blumen HM, Callisaya ML, De Cock A-M, Kressig RW et al. Falls, Cognitive Impairment, and Gait Performance: Results From the GOOD Initiative. Journal of the American Medical Directors Association. 2017;18(4):335-40. DOI: 10.1016/j.jamda.2016.10.008

68. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Archives ofInternal Medicine. 1999;159(7):677-85. PMID: 10218746

69. Coleman CI, Miao B, Bunz TJ, Sood N. Estimating the rate of fall-related intracranial hemorrhage in nonvalvular atrial fibrillation patients receiving oral anticoagulation. Journal of the American College of Cardiology. 2019;73(9):291. DOI: 10.1016/S0735-1097(19)30899-X

70. Xian Y, O'Brien EC, Liang L, Xu H, Schwamm LH, Fonarow GC et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA. 2017;317(10):1057. DOI: 10.1001/jama.2017.1371

71. Jankowska-Polanska B, Katarzyna L, Lidia A, Joanna J, Dudek K, Izabella U. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. Journal of geriatric cardiology: JGC. 2016;13(7):559-65. DOI: 10.11909/j.issn.1671-5411.2016.07.006

72. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Current Medical Research and Opinion. 2012;28(5):669-80. DOI: 10.1185/03007995.2012.677419

73. Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of Daily Dosing Frequency on Adherence to Chronic Medications Among Nonvalvular Atrial Fibrillation Patients. Advances in Therapy. 2012;29(8):675-90. DOI: 10.1007/s12325-012-0040-x

74. Rossi AP, Facchinetti R, Ferrari E, Nori N, Sant S, Masciocchi E et al. Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with nonvalvular atrial fibrillation. Journal of Thrombosis and Thrombolysis. 2018;46(2):139-44. DOI: 10.1007/s11239-018-1679-1

75. Andrade JG, Krahn AD, Skanes AC, Purdham D, Ciaccia A, Connors S. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Canadian Journal of Cardiology. 2016;32(6):747-53. DOI: 10.1016/j.cjca.2015.09.023

76. Mahtani KR, Heneghan CJ, Glasziou PP, Perera R. Reminder packaging for improving adherence to self-administered longterm medications. Cochrane Database of Systematic Reviews. 2011;9:CD005025. DOI: 10.1002/14651858.CD005025.pub3

77. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: Results from the Dresden NOAC Registry. Thrombosis and Haemostasis. 2016;115(05):939-49. DOI: 10.1160/TH15-10-0840

78. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal. 2016;37(14):1145-53. DOI: 10.1093/eurheartj/ehv466

79. Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S. Incidence of Dementia over Three Decades in the Framingham Heart Study. New England Journal of Medicine. 2016;374(6):523-32. DOI: 10.1056/NEJMoa1504327


Для цитирования:


Кобалава Ж.Д., Лазарев П.В., Федорова Д.Н. Когнитивная дисфункция на фоне фибрилляции предсердий: клинико-патогенетические ассоциации, диагностика и профилактика, аспекты применения антикоагулянтной терапии. Кардиология. 2019;59(10):66-77. https://doi.org/10.18087/cardio.2019.10.n612

For citation:


Kobalava Zh.D., Lazarev P.V., Fedorova D.N. Cognitive Dysfunction at the Background of Atrial Fibrillation: Clinical-Pathological Aspects, Diagnostics and Prevention, Issues of the Use of the Application of Anticoagulant Therapy. Kardiologiia. 2019;59(10):66-77. (In Russ.) https://doi.org/10.18087/cardio.2019.10.n612

Просмотров: 592


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)